This interaction suggests PHF6’s essential function in leukemia development and underscores the potential of combining JAK3 and MDM2 inhibitors as a targeted therapy for T-ALL patients with co-mutation of PHF6 and JAK3 (Yuan et al., 2022). The gene discussed is JAK3; the disease is acute lymphoblastic leukemia.